<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114997</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00020608</org_study_id>
    <nct_id>NCT01114997</nct_id>
  </id_info>
  <brief_title>Effect of Lidocaine and Esmolol to Improve the Quality of Recovery</brief_title>
  <official_title>Effect of Lidocaine and Esmolol Alone or in Combination to Improve the Quality of Recovery, Maintaining Hemodynamic Stability During Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, randomized, double-blinded, active-controlled study is:

      To assess the effectiveness of systemic administration of lidocaine and esmolol in
      combination (vs. either drug alone) will result in improved postoperative outcomes for
      patients undergoing abdominal surgery (e.g., less pain and postoperative constipation, nausea
      and vomiting, faster return of bowel function, resumption of normal activities of daily
      living), leading to a shorten length of hospital stay, maintaining hemodynamic stability
      during general anesthesia, when administered as intravenous adjuvants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Finding the optimal combination of anesthetic adjuvant drugs for maintaining hemodynamic
      stability during surgery is a challenge (1-3). Traditionally, potent opioid analgesics like
      fentanyl and its newer analogs have been used for this purpose. However, use of opioid
      compounds is associated with well-known side effects (e.g., ventilatory depression,
      postoperative nausea and vomiting, constipation, ileus, bladder dysfunction, urinary
      retention, pruritus, drowsiness and sedation). All of these common side effects interfere
      with the early recovery process and contribute to a delayed resumption of normal activities
      (4, 5). Increasingly, non-opioid analgesics (e.g. β-blockers and local anesthetics) are being
      utilized as adjuvant drugs during surgery for treatment of acute hyperdynamic responses
      (increased catecholamine release) during surgery, as well as, facilitation of the recovery
      process after surgery because of their anesthetic and analgesic-sparing effects. The
      β-blocking drugs, esmolol and labetalol have been used as an alternative to short-acting
      opioid analgesics for controlling the transient, acute autonomic responses during surgery
      (5-8), They have been shown to reduce the anesthetic requirement during intravenous
      (propofol) or volatile-based anesthesia (6,7,10-13) and to decrease opioid consumption
      intraoperatively and in the PACU (8). They may also improve hemodynamic stability during
      induction and emergence from anesthesia in the perioperative and early postoperative period
      and facilitate the resumption of normal activities after major surgical procedures. The
      anesthetic and analgesic-sparing effects of β -blockers also lead to a faster emergence from
      anesthesia and reduce postoperative opioid side effects (e.g., PONV) (14-18). Perioperative
      intravenous esmolol has shown improvement in perioperative outcomes, decreases acute
      hemodynamic responses, reduces anesthetics and opioids use during anesthesia, facilitates a
      faster emergence from anesthesia, reduces intraoperative and postoperative opioid
      requirements, reduces side effects as such as pruritus, constipation, ileus, nausea and
      vomiting (PONV) and thereby shortens the hospital stay. (3, 7, 13, 18)

      Local anesthetics like lidocaine possess analgesic, antihyperalgesic and anti-inflammatory
      properties. Perioperative intravenous lidocaine has shown improvement in perioperative
      outcomes in patients undergoing abdominal surgery to decrease intraoperative requirement of
      Inhalants/Intravenous agents, opioid consumption, postoperative pain, fatigue, nausea and
      vomiting scores, maintain hemodynamic stability, facilitate a more rapid recovery of
      gastrointestinal function, improve postoperative recovery, fast resumption of normal
      activities of daily living and shorten length of hospital stay, when administered as an
      adjuvant during surgery.(19,23-29,33)

      Theoretically, it would be extremely beneficial to administer an adjuvant (to patients
      undergoing abdominal surgery) that is capable of effectively controlling autonomic responses
      during surgery, while providing a faster recovery with fewer side effects. Preliminary data
      suggests that the perioperative effects of systemic administration of lidocaine and esmolol
      is most effective in facilitating bowel recovery, decreasing opioid consumption in the
      intra/postoperative period, and shorten length of hospital stay with early recovery.
      Therefore, we designed this prospective, randomized, double-blinded, active-controlled study
      to test the hypothesis that systemic administration of lidocaine and esmolol in combination
      (vs. either drug alone) for maintenance of hemodynamic stability during surgery will result
      in improved postoperative outcomes for patients undergoing abdominal surgery (e.g., less pain
      and postoperative nausea and vomiting, and faster return of bowel function and resumption of
      normal activities of daily living); leading to a shorten length of hospital stay.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The early report didn't show any benefit.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Operative Pain</measure>
    <time_frame>1 day</time_frame>
    <description>Outcome had a duration of one day at post-anesthesia care unit (PACU) Postoperative pain measured using a Verbal Rating Scale (VRS) Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Post Operative Pain One Month After Surgery</measure>
    <time_frame>1 month</time_frame>
    <description>Highest Post Operative pain one month after surgery, using a verbal rating score from 0 (no pain) to 10 (highest level of pain).
Patient received a post-operative follow-up call one month after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption Obtained From the Recorded Data</measure>
    <time_frame>1 day</time_frame>
    <description>Postoperative use of opioid consumption inside hospital (recorded by study staff and data obtained from patient charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Nausea One Day After Surgery</measure>
    <time_frame>1day</time_frame>
    <description>Postoperative nausea using a Verbal Rating Scale Outcomes measured at the first day after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Normal Activities of Daily Living Using Follow up Questionnaires</measure>
    <time_frame>1 month</time_frame>
    <description>Description: return to normal activities of daily living(including dietary intake, bowel and bladder function, physical activities)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>1 month</time_frame>
    <description>Patient satisfaction using a verbal rating scale from 0 to 10 0= Not satisfied 10= Excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-anesthesia Care Unit (PACU) Stay</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pain</condition>
  <condition>Constipation</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine + Esmolol (Combo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performed with the administration of both drugs.
Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine + Esmolol (Combo)</intervention_name>
    <description>Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)
Maintenance Infusion rate after Induction:
Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
    <arm_group_label>Lidocaine + Esmolol (Combo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo abdominal surgical procedures

          -  Willingness and ability to sign an informed consent document

          -  No allergies to anesthetic or analgesic medications

          -  18 - 80 years of age

          -  American Society of Anesthesiologists (ASA) physical status classification: Class I -
             III adults of either sex

          -  Women of childbearing potential must be currently practicing an acceptable form of
             birth control, and have a negative urine or blood pregnancy test

          -  Patients with systolic blood pressure greater than 80 and less than 150 at baseline,
             diastolic blood pressure less than 100 at baseline.

        Exclusion Criteria:

          -  Inability to comprehend the pain assessment tools.

          -  Patients with known allergy, hypersensitivity or contraindications to anesthetic or
             analgesic medications

          -  Patients with clinically-significant medical conditions, such as brain, heart, kidney,
             endocrine, or liver diseases,

          -  Peptic ulcer disease or bleeding disorders

          -  Patients with history of hepatic, renal, cardiac failure, organ transplant, or
             diabetes

          -  Patients with reactive airway disease (asthma)

          -  Patients with seizures

          -  Chronic use of ß-blocker or calcium channel blocker

          -  Morbid obesity (body mass index &gt;40)

          -  Pregnant or lactating women

          -  Subjects with a history of alcohol or drug abuse within the past 3 months

          -  Any other conditions or use of any medication which may interfere with the conduct of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roya Yumul, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <results_first_submitted>May 16, 2016</results_first_submitted>
  <results_first_submitted_qc>May 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2016</results_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Roya Yumul, M.D.,PhD.</investigator_full_name>
    <investigator_title>Residency program director, Department of anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Lidocaine Infusion</keyword>
  <keyword>Esmolol Infusion</keyword>
  <keyword>Anesthetic adjuvant</keyword>
  <keyword>Abdominal surgery</keyword>
  <keyword>Pain management</keyword>
  <keyword>Hemodynamic stability</keyword>
  <keyword>Perioperative outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
        </group>
        <group group_id="P2">
          <title>Esmolol</title>
          <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
        </group>
        <group group_id="P3">
          <title>Lidocaine + Esmolol (Combo)</title>
          <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
        </group>
        <group group_id="B2">
          <title>Esmolol</title>
          <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
        </group>
        <group group_id="B3">
          <title>Lidocaine + Esmolol (Combo)</title>
          <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-Induction (Maintenance Infusion):
Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="8"/>
                    <measurement group_id="B2" value="44" spread="3"/>
                    <measurement group_id="B3" value="38" spread="10"/>
                    <measurement group_id="B4" value="41" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>California, United States</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Operative Pain</title>
        <description>Outcome had a duration of one day at post-anesthesia care unit (PACU) Postoperative pain measured using a Verbal Rating Scale (VRS) Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain</title>
          <description>Outcome had a duration of one day at post-anesthesia care unit (PACU) Postoperative pain measured using a Verbal Rating Scale (VRS) Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="4"/>
                    <measurement group_id="O2" value="2" spread="2"/>
                    <measurement group_id="O3" value="4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Post Operative Pain One Month After Surgery</title>
        <description>Highest Post Operative pain one month after surgery, using a verbal rating score from 0 (no pain) to 10 (highest level of pain).
Patient received a post-operative follow-up call one month after surgery.</description>
        <time_frame>1 month</time_frame>
        <population>Experience of pain at home</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post Operative Pain One Month After Surgery</title>
          <description>Highest Post Operative pain one month after surgery, using a verbal rating score from 0 (no pain) to 10 (highest level of pain).
Patient received a post-operative follow-up call one month after surgery.</description>
          <population>Experience of pain at home</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption Obtained From the Recorded Data</title>
        <description>Postoperative use of opioid consumption inside hospital (recorded by study staff and data obtained from patient charts)</description>
        <time_frame>1 day</time_frame>
        <population>Opioid: Hydromorphone</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption Obtained From the Recorded Data</title>
          <description>Postoperative use of opioid consumption inside hospital (recorded by study staff and data obtained from patient charts)</description>
          <population>Opioid: Hydromorphone</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1"/>
                    <measurement group_id="O2" value="1" spread="0.8"/>
                    <measurement group_id="O3" value="1.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Nausea One Day After Surgery</title>
        <description>Postoperative nausea using a Verbal Rating Scale Outcomes measured at the first day after surgery</description>
        <time_frame>1day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Nausea One Day After Surgery</title>
          <description>Postoperative nausea using a Verbal Rating Scale Outcomes measured at the first day after surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Normal Activities of Daily Living Using Follow up Questionnaires</title>
        <description>Description: return to normal activities of daily living(including dietary intake, bowel and bladder function, physical activities)</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Normal Activities of Daily Living Using Follow up Questionnaires</title>
          <description>Description: return to normal activities of daily living(including dietary intake, bowel and bladder function, physical activities)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient satisfaction using a verbal rating scale from 0 to 10 0= Not satisfied 10= Excellent</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine (12.5-25 mcg/kg/min) + Esmolol (7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient satisfaction using a verbal rating scale from 0 to 10 0= Not satisfied 10= Excellent</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="0.8"/>
                    <measurement group_id="O2" value="9.2" spread="1"/>
                    <measurement group_id="O3" value="8.3" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-anesthesia Care Unit (PACU) Stay</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Pre-Induction:
Esmolol Loading dose: 750 mcg/Kg (0.75 mg/kg)
Post-Induction:
Infusion dose 7.5 - 15 mcg /kg/min</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine + Esmolol (Combo)</title>
            <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-anesthesia Care Unit (PACU) Stay</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236" spread="147"/>
                    <measurement group_id="O2" value="116" spread="38"/>
                    <measurement group_id="O3" value="214" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>Pre-Induction:
Lidocaine Loading: 1 mg/kg
Post- Induction:
Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)</description>
        </group>
        <group group_id="E2">
          <title>Esmolol</title>
          <description>Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min</description>
        </group>
        <group group_id="E3">
          <title>Lidocaine + Esmolol (Combo)</title>
          <description>Pre-induction:
Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
Post-induction:
Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roya Yumul</name_or_title>
      <organization>Cedars Sinai Medical Center</organization>
      <phone>310-423-1682</phone>
      <email>Roya.Yumul@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

